Yellow fever vaccine seroconversion in travelers

Am J Trop Med Hyg. 2011 Oct;85(4):748-9. doi: 10.4269/ajtmh.2011.11-0363.

Abstract

To assess immunity after yellow fever (YF) 17D live-attenuated vaccination, we measured the antibody levels before vaccination and at 21 days and 8 months after vaccination in YF-naïve travelers. Thirty subjects were enrolled in the study, with 100% providing sera at 21 days and 86.6% providing sera at 8 months. All subjects seroconverted by day 21, and the geometric mean titers of the anti-YF antibodies decreased between day 21 and month 8 from 6,451 to 1,246. This study corroborates the high rates of seroconversion achieved by the live-attenuated YF vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Viral / blood
  • Female
  • Humans
  • Male
  • Middle Aged
  • Travel*
  • Yellow Fever Vaccine / administration & dosage*
  • Yellow Fever Vaccine / immunology
  • Young Adult

Substances

  • Antibodies, Viral
  • Yellow Fever Vaccine